Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2018-N-2485]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 27 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
 DATES: Approval is withdrawn as of September 7, 2018.
 FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, 
                        *Trang.Tran@fda.hhs.gov*.


SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. Application No.
Drug
ApplicantANDA 061467
Pyocidin-Otic (hydrocortisone and polymyxin B sulfate) Otic Solution, 5 milligrams (mg)/10,000 units per milliliter (mL)
Fougera Pharmaceuticals, Inc., 60 Baylis Rd., P.O. Box 2006, Melville, NY 11747.ANDA 061653
Tetrex (tetracycline phosphate complex) Capsules, Equivalent to (EQ) 100 mg Hydrochloride (HCl), EQ 250 mg HCl and EQ 500 mg HCl
Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543.ANDA 061658
Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg
Do.ANDA 061711
Penicillin V Potassium Tablets
Do.ANDA 061721
Ampicillin Capsules, 250 mg and 500 mg
Do.ANDA 061726
Azotrex (phenazopyridine HCl, sulfamethizole and tetracycline phosphate complex) Capsules, 50 mg/250 mg/125 mg
Do.ANDA 061790
Hetacillin Potassium
Do.ANDA 061887
Bristamycin (erythromycin stearate) Tablets, EQ 250 mg base
Do.ANDA 061888
Bristacycline (tetracycline HCl) Capsules, 250 mg and 500 mg
Do.ANDA 061889
Tetrex (tetracycline phosphate complex) Capsules, EQ 250 mg HCl and EQ 500 mg HCl
Do.ANDA 061890
Azotrex (phenazopyridine HCl, sulfamethizole, and tetracycline) Capsules, 50 mg/250 mg/125 mg
Do.ANDA 061891
Tetrex-S (tetracycline) Syrup, 125 mg/5 mL
Do.ANDA 061975
Cephradine Powder for Injection
Do.ANDA 062168
Cephradine Tablets
Do.ANDA 062259
Amphotericin B for Use in Parenteral Products
Do.ANDA 062543
Mycolog (nystatin, neomycin sulfate, gramicidin, and triamcinolone acetonide) Ointment
Do.ANDA 071793
Foamcoat (aluminum hydroxide; magnesium trisilicate) Chewable Tablets, 80 mg/20 mg (OTC)
Guardian Drug Co., 2 Charles Court, Dayton, NJ 08810.ANDA 072035
Nuprin (ibuprofen) Tablets, 200 mg
Bristol-Myers Squibb Co.ANDA 072036
Nuprin (ibuprofen) Tablets, 200 mg
Do.ANDA 074911
Phrenilin with Caffeine and Codeine (acetaminophen, butalbital, caffeine, and codeine phosphate) Capsules, 325 mg/50 mg/40 mg/30 mg
Valeant Pharmaceuticals North America, LLC, 400 Somerset Corporate Blvd., Bridgewater, NJ 08807.ANDA 074944
Atracurium Besylate Injection, 10 mg/mL
Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.ANDA 075206
Cytosar-U (cytarabine) for Injection USP, 100 mg/vial, 500 mg/vial, 1 gram (g)/vial, and 2 g/vial
Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.ANDA 077337
Rosiglitazone Maleate and Metformin HCl Tablets, EQ 1 mg base/500 mg, EQ 2 mg base/500 mg, EQ 4 mg base/500 mg, EQ 2 mg base/1 g, and EQ 4 mg base/1 g
Do.ANDA 077930
Meloxicam Tablets, 7.5 mg and 15 mg
Impax Laboratories, Inc., 30831 Huntwood Ave., Hayward, CA 94544.ANDA 080658
Procaine HCl Injection, 1% and 2%
Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.ANDA 083128
Hydrocortisone Acetate Injectable Suspension, 25 mg/mL
Do.ANDA 090181
Ifosfamide for Injection, 1 g/20 mL and 3 g/60 mL
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.
 
 
 Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of September 7, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on September 7, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: August 3, 2018. Leslie Kux, Associate Commissioner for Policy.


[FR Doc. 2018-16985 Filed 8-7-18; 8:45 am] BILLING CODE 4164-01-P